National Health Investors price target raised to $76 from $70 at Truist

Truist analyst Michael Lewis raised the firm’s price target on National Health Investors (NHI) to $76 from $70 but keeps a Hold rating on the shares. The firm is adjusting its model to reflect the REIT’s more advantageous cost of debt and equity capital, noting that the market is giving National Health the green light to make new investments, the analyst tells investors in a research note. Truist adds however that the stock is not cheap relative to peers’ or its own history.